ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Advancements in hydroxypropyl methylcellulose-polyethylene glycol hybrid excipients and their nanoformulations for controlled and ligand-directed biologic delivery.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the Versatility and Sustainability of Hydroxypropyl Methylcellulose (HPMC) in Modern Chemical Industry.Polymers · 2026Review
- Allosteric ligand-driven smart nanoconjugates for mutation-selective EGFR targeting: A precision approach to overcoming tyrosine kinase inhibitor resistance.BioImpacts : BI · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The delivery of biologic drugs presents unique formulation challenges due to their high molecular weight, instability in physiological environments, and complex pharmacokinetics. Hybrid excipient systems, particularly those combining hydroxypropyl methylcellulose (HPMC) and polyethylene glycol (PEG), offer a versatile platform for addressing these issues. Hydroxypropyl methylcellulose (HPMC), a semi-synthetic polymer, is widely recognized for its gel-forming ability, biocompatibility, and capacity to enable sustained drug release. Polyethylene glycol (PEG), a hydrophilic polyether, is commonly employed to enhance solubility, reduce protein aggregation, and improve mucosal permeability. This review presents a focused analysis of HPMC-PEG-based different formulation strategies that support controlled, sustained, and site-specific delivery of biologics across various routes including oral, nasal, ocular, parenteral, and pulmonary. Furthermore, the review discusses mechanistic insights, PEG-related immunogenicity concerns, and regulatory considerations that are critical for clinical translation. Key aspects such as formulation strategies, physicochemical properties, in vitro and in vivo performance, and targeting capabilities are discussed. Additionally, the challenges associated with the scale-up, regulatory approval, and potential toxicity of these hybrid systems are explored. By integrating physicochemical behavior with route-specific delivery outcomes, this review provides a consolidated, application-oriented perspective that bridges formulation science with therapeutic advancement in biologics. This distinguishes it from prior work and offers practical guidance for excipient scientists and pharmaceutical developers. This review also provides insights into the future directions and applications of HPMC-PEG hybrid excipients and the developed nanoformulations in personalized medicine and sustained-release drug product.
Indexed as
Identifiers
40682687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.